This move is set to bolster Rosemont’s capabilities in developing a wider range of dosage forms and modified release oral liquids. Pharma-Data has been instrumental in creating value-added
The company will develop these therapies to target human leukocyte antigen (HLA) Class II (HLA-II) in oncology field. The funding will support Yellowstone in its operational build, progression
New investors Mubadala Capital and Exor Ventures spearheaded this oversubscribed round. The Series B extension also saw participation from Qatar Investment Authority, alongside current stakeholders including Abingworth and
This new treatment is specifically indicated as a monotherapy for paediatric patients aged one month to two years with IS, provided the potential benefits justify the risk of
This therapy is currently being developed to treat chronic myeloid leukemia (CML) as well as other hematological cancers. If Takeda exercises this option, the company will have the
The alliance will harness the potential of traditional medical compounds in the fight against bacterial infections. Quadram’s TraDIS-Xpress platform will be utilised to innovate antibacterial treatments by studying
These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation
This partnership will focus on developing a translational medicine ecosystem and launching innovative research initiatives in Abu Dhabi. The second MoU outlines plans to design and develop a
This development follows the clearance for an investigational new drug (IND) application by the FDA for the asset last month. The fast track status is expected to expedite
A decision on the approval under the Prescription Drug User Fee Act (PDUFA) is anticipated on 25 January 2025. LEQEMBI is intended to treat AD patients having mild
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.